Search in our News Channels
|
|
Search in our Online Store
|
|
Neose Technologies Announces Initiation of Phase I Trial of GlycoPEG-GCSF |
|
|
|
10 Nov 2006 |
Today announced that its partner, BioGeneriX AG, a company of the ratiopharm Group, has begun dosing healthy volunteers in a Phase I clinical trial of GlycoPEG-GCSF, a long-acting, GlycoPEGylated™ granulocyte colony stimulating factor for the treatment of neutropenia.
HORSHAM, PA, USA | Nov 09, 2006 | Neose Technologies, Inc. (Nasdaq GM: NTEC) today announced that its partner, BioGeneriX AG, a company of the ratiopharm Group, has begun dosing healthy volunteers in a Phase I clinical trial of GlycoPEG-GCSF, a long-acting, GlycoPEGylated™ granulocyte colony stimulating factor for the treatment of neutropenia. The trial, which is being conducted in Western Europe, will evaluate the safety, pharmacokinetics and pharmacodynamics of GlycoPEG-GCSF versus Neulasta® in approximately 60 healthy volunteers. The Phase I trial is designed as a single-blind, randomized, ascending-dose study that will evaluate subcutaneous administration of GlycoPEG-GCSF.
“We are pleased to have our GlycoPEG-GCSF enter Phase I as the second Neose protein to enter human clinical trials this year. We hope that the data from the Phase I clinical program continues to demonstrate that our compound is competitive with the market leader,” said George J. Vergis, Ph.D., Neose president and chief executive officer.
About G-CSF and Neutropenia
G-CSF is prescribed to stimulate the production of neutrophils, and is approved for sale in major markets around the world for the treatment of neutropenia associated with myelosuppressive chemotherapy. Worldwide sales in the G-CSF category were approximately $4 billion in 2005.
Neutropenia is a severe reduction in the number of neutrophils (mature white blood cells) in the circulating blood, commonly associated with cancer chemotherapy. Patients with neutropenia are at increased risk of developing serious infection. If not treated promptly, neutropenia can be life-threatening.
About BioGeneriX
BioGeneriX was founded in June 2000 to develop biopharmaceutical drugs with known modes of action and established drug markets. With its internal resources and a large network of strategic partners and service providers, BioGeneriX develops a high-quality biotech portfolio for marketing and distribution by its parent company and global partners. For more information, visit its website at www.biogenerix.com.
About the ratiopharm Group
ratiopharm is Europe’s leading generics producer and in its home country Germany the top selling and most commonly prescribed pharmaceutical brand. The company produces high quality medicines and sells them at low prices. By doing so, it contributes to cost containment in the healthcare sector. With over 700 medicines, available exclusively from pharmacies, it has one of the widest product ranges in the business. ratiopharm sells 322 million pack units every year, meeting the needs of virtually all areas of medicine, from allergies to circulation problems and from gastroenteritis to toothaches. Founded in 1974, ratiopharm is now bringing its business model and experience to international markets. It is already active in 24 countries. In 2005, ratiopharm generated worldwide revenues of 1.6 billion Euros, of which 700 million Euros were from sales in Germany. For more information, visit its website at www.ratiopharm.de.
About Neose Technologies, Inc.
Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with aggregate sales in excess of $14 billion.
For more information, please visit www.neose.com.
Neose “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are “forward-looking statements” that involve risks and uncertainties, including without limitation the risk that GlycoPEG-GCSF fails in clinical trials, the risk that regulatory approval will not be received for additional trials or that our partner will not fund additional trials, the risk that we will never receive regulatory approval of GlycoPEG-GCSF and the risk that we will be unable to successfully commercialize or market GlycoPEG-GCSF. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the section of Neose’s Annual Report on Form 10-K for the year ended December 31, 2005, entitled “Factors Affecting the Company’s Prospects” and discussions of potential risks and uncertainties in Neose’s subsequent filings with the SEC.
SOURCE: Neose Technologies, Inc. |
|
For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01
La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L
|
 |
|
|
